Associate Director, Cancer Research Foundation, Immediate Past Chair of ECOG-ACRIN Renal Cancer Subcommittee, 750 Kappock Street, # 511, Bronx, NY 10463, USA.
Ther Adv Urol. 2013 Dec;5(6):338-53. doi: 10.1177/1756287213505672.
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the understanding of the molecular characterizations of subtypes of RCC with potential to lead to new therapeutic options. Additionally, the urologic oncology community is focusing on nephron-sparing surgical approaches with limited surgery if possible, and in conjunction with interventional radiologists, on ablative procedures for incidentally determined small renal masses. This report reviews some of the new biologic findings of adenocarcinoma of the kidney, and reviews the new therapeutics which continue to change the landscape for treatment of RCC.
肾细胞癌（RCC）的治疗一直备受关注，这在很大程度上是由于最近在晚期和转移性疾病的新治疗选择方面取得了成功。与此同时，人们对 RCC 亚型的分子特征的理解也取得了一些不太广为人知的进展，这有可能为新的治疗选择提供依据。此外，泌尿科肿瘤学领域的研究人员正在关注保留肾单位的手术方法，如果可能的话，尽量减少手术，并与介入放射科医生合作，对偶然发现的小肾肿瘤进行消融治疗。本报告回顾了肾腺癌的一些新的生物学发现，并回顾了不断改变 RCC 治疗格局的新疗法。
